Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Topadur Pharma AG has 1 pending office action in the Biotechnology & Pharmaceuticals sector. This matter is handled by 1 distinct examiner, SHTERENGARTS, SAMANTHA L, across a distinct art unit. This indicates a point of contact for the company's current patent prosecution efforts.
As the busiest examiner for the portfolio, SHTERENGARTS, SAMANTHA L is responsible for a pending office action. The lack of broader distribution across examiners or art units means the current prosecution outcome is tied to the examination perspective within the USPTO. Practitioners should focus on the specific feedback from this examiner to advance the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SHTERENGARTS, SAMANTHA L | 1 | 79.5% | +8.0% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18841618 | TOPICAL COMPOSITIONS AND USES THEROF | SHTERENGARTS, SAMANTHA L | 1623 | §103§112DP | Non-Final OA | — | Pending | Aug 26, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTopadur Pharma AG has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Samantha L Shterengarts has the most, with 1 of Topadur Pharma AG's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
